Emergent Biomarker(s) for Spinal Cord Injury
Traumatic brain injury and spinal cord injury (SCI) represents a great socioeconomic impact on any society because of their high mortality and in that they disable the most active members of the population. In the USA, yearly incidence of TBI is between 1800 and 2500 per million; incidence of SCI is approximately 700 cases per million. A modest estimate of total lifetime costs per TBI case in the USA is around $200 000,3 whereas for patients with SCI, it is close to $1,500,000.
Recently, it was established that in spinal cord injury, neurotoxicity biomarkers play important roles in post-traumatic white matter degeneration. Lab team in collaboration with Georgia Institute of Technology (Dr. LaPlaca) initiated investigations of metabolic and functional differences between brain and spinal cord injuries.
Dambinova, S.A. Neurodegradomics: the source of biomarkers for mild TBI and SCI. In: Biomarkers for TBI. Textbook. Royal Soc. Chemistry Pub. House, London, UK. In print for July, 2012, Chapter 4, 66-86.
Panov, A., Steuerwald, N., Vavilin, V., Dambinova, S.A., Bonkovsky, H.L. Role of neuronal mitochondrial metabolic phenotype in pathogenesis of ALS. In: Amyotrophic Lateral Sclerosis. 2012, Ed. Martin H. Maurer, INTECH Open Access Publisher, ISBN 979-953-307-199-1
Panov, A. Mitochondrial Dysfunctions and Markers of the Spinal Cord Injury. In: Biomarkers for TBI. Textbook. Royal Soc.Chemistry Publ House, London, UK. In print for July, 2012, Chapter 6, 106-121.